Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

NCT04400799 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

475

Enrollment

OTHER

Sponsor class

Stopped due to results from interim analysis

Conditions

COVID-19
Pulmonary Embolism, Deep Vein Thrombosis

Interventions

DRUG: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml

Sponsor

University of Zurich

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]